Lilly’s Donanemab, Now At FDA, Poised To Join Alzheimer’s Armamentarium

 
• By Jessica Merrill
Fighter Jets
Lilly believes donanemab is well positioned to join the Alzheimer's fight • Source: Shutterstock

More from Clinical Trials

More from R&D